Every AXLRx Atopic Dermatitis report, across 4 report types. Each is scoped to your asset and verified to a live source.
Dupilumab's 70% biologic share against JAK step-edits. A two-tier US payer landscape for IL-4Ra biologics and oral JAKs.
US atopic dermatitis epidemiology — 16.5M adults, the moderate-to-severe pool, and the atopic march that frames the biologic-eligible segment.
Topical-then-biologic step-therapy, JAK black-box PA gates, ICER's dupilumab-aligned and JAK-discount verdicts, and why Dupixent is not IRA-selected.
Dupilumab's 70% share sets the biologic entrenchment bar. The 2022 JAK boxed warning sets a second, harder gate for any oral entrant.
AXLRx publishes Competitive Intelligence, Disease Landscape, Payer & HTA, and Launch Readiness for Atopic Dermatitis. Each report is scoped to your asset, verified to a live source, and delivered in 72 hours.
Current Atopic Dermatitis coverage spans United States. Additional markets can be commissioned against the same evidence standard.
Every figure is cited to a live source at the point of writing and re-checked in an independent audit pass. The latest Atopic Dermatitis reports were updated July 2026.